Preliminary long-term data for WTX101 in Wilson Disease accepted as a late-breaker presentation at EASL Annual Meeting
Wilson Therapeutics AB (publ), announced today that preliminary long-term efficacy and safety data from the ongoing extension phase of the company’s Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class copper-protein-binding agent under investigation as a novel therapy for Wilson Disease, has been accepted as a late-breaker poster presentation at The International Liver Congress™ 2018, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Paris, France, 11-15 April, 2018. An abstract of the poster is available today,